rs,
change Plaza, Bandra-Kurla Complex, Bandra, Mumbai - 400 051. Symbol: HIKAL BSE Ltd., P J Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 524735 Dear Sir/Madam, Subject: Results Presentati
₹ 319 crore
footprint, and long-standing partnerships provide resilience. Consolidated revenue for Q2 stood at ₹ 319 crore, with EBITDA at ₹ 8 crore. For H1 FY26, revenue stood at ₹ 699 crore, with EBITDA at ₹ 32 crore. L
₹ 8 crore
partnerships provide resilience. Consolidated revenue for Q2 stood at ₹ 319 crore, with EBITDA at ₹ 8 crore. For H1 FY26, revenue stood at ₹ 699 crore, with EBITDA at ₹ 32 crore. Lower than expected sales d
₹ 699 crore
idated revenue for Q2 stood at ₹ 319 crore, with EBITDA at ₹ 8 crore. For H1 FY26, revenue stood at ₹ 699 crore, with EBITDA at ₹ 32 crore. Lower than expected sales due to deferment during the quarter led to u
₹ 32 crore
at ₹ 319 crore, with EBITDA at ₹ 8 crore. For H1 FY26, revenue stood at ₹ 699 crore, with EBITDA at ₹ 32 crore. Lower than expected sales due to deferment during the quarter led to under absorption of fixed co
₹190 crore
uring the quarter led to under absorption of fixed costs. Pharmaceutical business revenue stood at ₹190 crore, with an EBIT margin of -9.2%. Following the US FDA audit in February 2025, we received an OAI and
9.2%
ption of fixed costs. Pharmaceutical business revenue stood at ₹190 crore, with an EBIT margin of -9.2%. Following the US FDA audit in February 2025, we received an OAI and warning letter, leading to H1
₹ 129 crore
tively engaged to expedite a positive resolution. Our crop protection business reported revenue of ₹ 129 crore, with an EBIT margin of -7.4%. While globally volumes continue to stabilise, the dynamic demand pa
7.4%
resolution. Our crop protection business reported revenue of ₹ 129 crore, with an EBIT margin of -7.4%. While globally volumes continue to stabilise, the dynamic demand patterns and structural shifts a
6.5%
MMARY COMMENTARY Rs. In Crs Revenue EBITDA EBITDA% PAT EPS Q1FY26 Q2FY25 Q2FY26 380 25 6.5% (23) (1.84) 453 75 16.5% 18 1.47 319 8 2.6% (35) (2.82) CONSOLIDATED: REVENUE SPLIT%
16.5%
Revenue EBITDA EBITDA% PAT EPS Q1FY26 Q2FY25 Q2FY26 380 25 6.5% (23) (1.84) 453 75 16.5% 18 1.47 319 8 2.6% (35) (2.82) CONSOLIDATED: REVENUE SPLIT% In % Q1FY26 Q2FY25 Q2FY26
2.6%
% PAT EPS Q1FY26 Q2FY25 Q2FY26 380 25 6.5% (23) (1.84) 453 75 16.5% 18 1.47 319 8 2.6% (35) (2.82) CONSOLIDATED: REVENUE SPLIT% In % Q1FY26 Q2FY25 Q2FY26 Pharmaceuticals Crop-Pr